Fixed-Dose Inotuzumab Produces Deep Early Responses in B-ALL
A 39-patient prospective study from Qingdao University reported high remission and MRD-negativity rates with a fixed-dose inotuzumab ozogamicin regimen in newly diagnosed B-ALL. The results support further testing of an antibody-drug conjugate-centered frontline strategy,…
